Los Angeles Capital Management LLC Sells 153,181 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Los Angeles Capital Management LLC decreased its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 69.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,653 shares of the biotechnology company's stock after selling 153,181 shares during the period. Los Angeles Capital Management LLC's holdings in Heron Therapeutics were worth $104,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Y Intercept Hong Kong Ltd bought a new position in shares of Heron Therapeutics in the third quarter valued at $39,000. Capstone Investment Advisors LLC bought a new position in shares of Heron Therapeutics in the third quarter valued at $45,000. King Wealth Management Group increased its holdings in shares of Heron Therapeutics by 52.3% in the third quarter. King Wealth Management Group now owns 23,299 shares of the biotechnology company's stock valued at $46,000 after buying an additional 8,000 shares in the last quarter. Glenmede Trust Co. NA increased its holdings in shares of Heron Therapeutics by 49.6% in the third quarter. Glenmede Trust Co. NA now owns 31,903 shares of the biotechnology company's stock valued at $63,000 after buying an additional 10,578 shares in the last quarter. Finally, Intech Investment Management LLC bought a new position in shares of Heron Therapeutics in the third quarter valued at $72,000. Institutional investors own 80.01% of the company's stock.

Heron Therapeutics Trading Up 1.3 %

NASDAQ:HRTX traded up $0.03 during trading hours on Friday, hitting $2.39. 1,532,645 shares of the stock traded hands, compared to its average volume of 1,875,967. The firm has a 50 day moving average price of $1.77 and a 200 day moving average price of $1.73. Heron Therapeutics, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $3.93. The firm has a market cap of $364.07 million, a price-to-earnings ratio of -13.28 and a beta of 1.55.

Remove Ads

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.05. The company had revenue of $40.78 million for the quarter, compared to analysts' expectations of $37.37 million. Research analysts predict that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on HRTX. Needham & Company LLC reissued a "buy" rating and set a $4.00 target price on shares of Heron Therapeutics in a research note on Friday, February 28th. StockNews.com downgraded shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.